Montclair, CA – Ingredients by Nature (IBN)—supplier of innovative, customizable, and science-based food ingredients—has announced approval by the USPTO of a second patent for IBN’s use of eriocitrin in its ingredient formulations, such as is found in Eriomin™.
The eriocitrin patent claim is stated as a “method of increasing GLP-1 levels in a subject in need thereof, comprising administering a composition comprising eriocitrin to the subject.” GLP-1 helps to maintain appropriate amounts of insulin secretion and glucose uptake. The patent further solidifies the use of eriocitrin to support individuals with unhealthy levels of fasting blood glucose, such as prediabetics, by administering 50-600 mg of the citrus flavonoid for increased GLP-1 levels. This is in addition to the recent approval for an amendment of IBN’s previous eriocitrin patent #10596185. That revision has increased the dosage claim of eriocitrin from 100-200 mg to 25-800 mg for the lowering of glucose levels.
“There are multiple facets to prediabetes management and increasing GLP-1 plays a vital role in helping to support healthy blood glucose levels,” said Rob Brewster, president of IBN. “The approval of our second eriocitrin patent provides strong support for our efforts to raise awareness of the flavonoid’s multi-faceted potential. We also have several more very promising human clinicals in process and hope to see some of them published soon.”
Eriocitrin is the primary citrus flavonoid used in IBN’s Eriomin ingredients. Two versions of Eriomin are currently available, Eriomin Glucose for prediabetes management and Eriomin Esport for a healthy gaming lifestyle, which help maintain blood glucose levels within the normal range. IBN is committed to doing more research that investigates Eriomin’s benefits for both of these categories and others over the coming years.
To learn more about eriocitrin and Eriomin’s benefits, visit Eriomin.com.
About Ingredients by Nature
With over 80 years of experience in the natural products industry, Ingredients by Nature (IBN) formulates, manufactures and markets science-based ingredients, proprietary extracts and formula innovations for applications in dietary supplements, functional foods & beverages, cosmetics and animal nutrition. IBN currently offers more than 300 ingredient variations, including probiotics and various citrus-derived ingredients—flavonoids and fibers—along with its custom, contract manufacturing and powder processing services. IBN’s lemon flavonoid blend Eriomin is backed by a human clinical and supports efforts toward prediabetes management and a healthy gaming lifestyle. IBN also recently acquired Sytrinol for heart health support.
This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.